Logo

Substandard Calcium and Vitamin D3 Tablets: Karnataka HC Rejects Pharma Firm's Plea to Quash Proceedings

Ravin Yadav
Add Court Book as a preferred source on Google

Karnataka High Court dismisses Life Vision Healthcare's plea to quash proceedings over allegedly substandard Calcium and Vitamin D3 tablets, holding that the allegations warrant a full-fledged trial. - Life Vision Healthcare & Anr. v. State of Karnataka

Substandard Calcium and Vitamin D3 Tablets: Karnataka HC Rejects Pharma Firm's Plea to Quash Proceedings

The Karnataka High Court has refused to quash criminal proceedings against pharmaceutical manufacturer Life Vision Healthcare and its Managing Partner over allegations that calcium and Vitamin D3 tablets failed to meet prescribed quality standards. Justice Rajesh Rai K held that the allegations required examination at trial and dismissed the company's petition.

Background

The complaint concerned Impcal Tablets (Calcium Orotate with Vitamin D3 Tablets I.P.), Batch No. LTA-2497, manufactured in September 2019 and expiring in February 2021.

A drug sample was collected on February 18, 2020, from a pharmaceutical establishment in Bengaluru. It was subsequently sent for laboratory analysis on February 20, 2020. The Government Analyst's report, received on August 24, 2020, declared the sample 'Not of Standard Quality' concerning its Vitamin D3 assay.

The company and its Managing Partner approached the High Court seeking to quash proceedings pending before the Special Court for Economic Offences, Bengaluru, under Sections 18(a)(i) and 27(d) of the Drugs and Cosmetics Act, 1940.

Court Book subscription: bare acts, legal drafts, court judgments and ad-free legal news, plans from ₹30/month

The petitioners argued that the drug sample was not forwarded for analysis immediately after seizure and that the delay affected their statutory right to seek re-analysis. They also contended that the Managing Partner could not be prosecuted merely because of his position in the company.

Rejecting these submissions at this stage, the Court noted that the sample had been forwarded within two days of seizure.

The Court observed:

"Therefore, forwarding the seized drug sample for chemical analysis within two days cannot, in the facts and circumstances of the present case, be construed as an undue or unexplained delay."

The Court also noted that the petitioners were informed about the test report on August 28, 2020, but sought re-analysis only on April 15, 2021, after the drug's shelf life had expired in February 2021.

On the Managing Partner's liability, the Court found that the complaint contained specific allegations indicating his involvement in the company's affairs and day-to-day functioning.

The Court further observed:

"The allegations, if established, have a direct bearing on public health and cannot be lightly brushed aside at this stage."

Holding that the matter warranted a full-fledged trial, the High Court dismissed the criminal petition without expressing any opinion on the merits of the case.

It clarified that the petitioners remained free to raise their contentions before the trial court.

Case Details

Case Title: Life Vision Healthcare & Anr. v. State of Karnataka

Case Number: Criminal Petition No. 1600 of 2024

Judge: Justice Rajesh Rai K

Decision Date: 2 November 2026

PDF
Download Order
Free access
Open PDF

Take CourtBook Everywhere

Access your account on the go with our mobile app.

Get it on Google PlayDownload on the App Store
Join the Court Book WhatsApp channel for latest judgments, notifications, legal news and exam updates